{"protocolSection":{"identificationModule":{"nctId":"NCT01544179","orgStudyIdInfo":{"id":"D791LC00001"},"organization":{"fullName":"AstraZeneca","class":"INDUSTRY"},"briefTitle":"A Study of IRESSA Treatment Beyond Progression in Addition to Chemotherapy Versus Chemotherapy Alone","officialTitle":"A Phase III Randomised, Double Blind, Placebo Controlled, Parallel, Multicentre Study to Assess the Efficacy and Safety of Continuing IRESSA 250 mg in Addition to Chemotherapy Versus Chemotherapy Alone in Patients Who Have Epidermal Growth Factor Receptor (EGFR) Mutation Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) and Have Progressed on First Line IRESSA","acronym":"IMPRESS"},"statusModule":{"statusVerifiedDate":"2020-09","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2012-03-15","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2014-05-05","type":"ACTUAL"},"completionDateStruct":{"date":"2019-11-20","type":"ACTUAL"},"studyFirstSubmitDate":"2012-02-15","studyFirstSubmitQcDate":"2012-03-02","studyFirstPostDateStruct":{"date":"2012-03-05","type":"ESTIMATED"},"resultsFirstSubmitDate":"2015-04-29","resultsFirstSubmitQcDate":"2016-01-19","resultsFirstPostDateStruct":{"date":"2016-02-15","type":"ESTIMATED"},"lastUpdateSubmitDate":"2020-09-24","lastUpdatePostDateStruct":{"date":"2020-09-25","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"AstraZeneca","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"The purpose of this study is to assess the efficacy and safety of gefitinib in patients who have progressed on first line gefitinib, comparing continuing gefitinib in addition to cisplatin plus pemetrexed combination chemotherapy versus cisplatin plus pemetrexed combination chemotherapy alone.","detailedDescription":"A Phase III Randomised, Double blind, Placebo controlled, Parallel, Multicentre Study to Assess the Efficacy and Safety of continuing IRESSA 250 mg in addition to Chemotherapy versus Chemotherapy alone in Patients who have Epidermal Growth Factor Receptor (EGFR) Mutation Positive Locally advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) and have progressed on First Line IRESSA."},"conditionsModule":{"conditions":["Non-Small Cell Lung Cancer"],"keywords":["Non Small Cell Lung Cancer","Gefitinib","Pemetrexed","Treatment Beyond Progression"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":265,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Gefitinib","type":"EXPERIMENTAL","description":"Gefitinib and cisplatin plus pemetrexed combination chemotherapy","interventionNames":["Drug: Gefitinib","Drug: Pemetrexed","Drug: Cisplatin"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","description":"Placebo and cisplatin plus pemetrexed combination chemotherapy.","interventionNames":["Drug: Placebo","Drug: Pemetrexed","Drug: Cisplatin"]}],"interventions":[{"type":"DRUG","name":"Gefitinib","description":"Investigational Drug","armGroupLabels":["Gefitinib"]},{"type":"DRUG","name":"Placebo","description":"Matching placebo as comparator","armGroupLabels":["Placebo"]},{"type":"DRUG","name":"Pemetrexed","description":"Chemotherapy (concomitant therapy)","armGroupLabels":["Gefitinib","Placebo"]},{"type":"DRUG","name":"Cisplatin","description":"Chemotherapy (concomitant therapy)","armGroupLabels":["Gefitinib","Placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Progression-Free Survival (Site Read, Investigator Assessment)","description":"PFS is the time from randomisation until the date of objective disease progression as defined by Response Evaluation Criteria In Solid Tumours (RECIST version 1.1) or death (by any cause in the absence of progression). Progression is defined using RECIST (v1.1), as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5mm.","timeFrame":"Radiologic evaluations were carried out every 6 weeks from randomization until documented progression, withdrawal of consent, loss to follow up, death or the primary data cut off (DCO) for the analysis, assessed up to 50 weeks"},{"measure":"Median Progression-Free Survival (Site Read, Investigator Assessment)","description":"PFS is the time from randomisation until the date of objective disease progression as defined by Response Evaluation Criteria In Solid Tumours (RECIST version 1.1) or death (by any cause in the absence of progression). Progression is defined using RECIST (v1.1), as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5mm.","timeFrame":"Radiologic evaluations were carried out every 6 weeks from randomization until documented progression, withdrawal of consent, loss to follow up, death or the primary data cut off (DCO) for the analysis, assessed up to 50 weeks"}],"secondaryOutcomes":[{"measure":"Overall Survival (OS)","description":"OS is the time from the date of randomisation until death due to any cause. Any subject not known to have died at the time of analysis will be censored based on the last recorded date on which the subject was known to be alive.","timeFrame":"Following progression survival data was collected every 8 weeks until documentation of death, withdrawal of consent, loss to follow-up or the final data cut-off, whichever occurs first."},{"measure":"Median Overall Survival (OS) at Time of PFS Analysis","timeFrame":"Baseline and then every 6 weeks after randomization until objective disease progression. OS is then assessed 8 weekly following PFS progression up to PFS analysis data cut off."},{"measure":"Objective Response Rate (ORR) (Site Read Data)","description":"ORR rate is defined as the number (%) of subjects with at least one visit response of Complete Response (CR) or Partial Response (PR) , as defined by Response Evaluation Criteria in Solid Tumours (RECIST v1.1) for target lesions and assessed by CT or MRI. CR, Disappearance of all target lesions; PR, ≥30% decrease in the sum of the longest diameter of target lesions. Data obtained up until progression, or last evaluable assessment in the absence of progression, was included in the assessment of ORR.","timeFrame":"Radiologic evaluations were carried out every 6 weeks from randomization until documented progression, withdrawal of consent, loss to follow up, death or the primary data cut off (DCO) for the analysis."},{"measure":"Disease Control Rate (DCR)","description":"DCR is the percentage of patients who achieve disease control at 6 weeks following randomisation. DCR is defined as a Best Objective Response (BOR) of Complete Response, Partial Response or Stable Disease, as defined by Response Evaluation Criteria in Solid Tumours (RECIST v1.1) for target lesions and assessed by CT or MRI. CR, Disappearance of all target lesions; PR, ≥30% decrease in the sum of the longest diameter of target lesions; SD, neither sufficient shrinkage to qualify for PR not sufficient increase to qualify for Progressive Disease (PD); PD, ≥20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study, and the sum must have shown an absolute increase of ≥5mm","timeFrame":"Radiologic evaluations were carried out every 6 weeks from randomization until documented progression, withdrawal of consent, loss to follow up, death or the primary data cut off (DCO) for the analysis."},{"measure":"Improvement in Trial Outcome Index","description":"An improvement is defined as a change from baseline of ≥ +6 (0-84 score range). Measured by the Functional Assessment of Cancer Therapy for Lung Cancer (FACT-L) questionnaire.","timeFrame":"At visits 2-8, then every 6 weeks until progression, at progression or treatment discontinuation, and every 8 weeks after progression until PFS analysis data cut off."},{"measure":"Time to Worsening in Trial Outcome Index","description":"A worsening is defined as a change from baseline of ≤ -6 (0-84 score range). Measured by the Functional Assessment of Cancer Therapy for Lung Cancer (FACT-L) questionnaire","timeFrame":"At visits 2-8, then every 6 weeks until progression, at progression or treatment discontinuation, and every 8 weeks after progression until PFS analysis data cut off."},{"measure":"Improvement in FACT-L Total Score","description":"An improvement is defined as a change from baseline of ≥ +6 (0-136 score range). Measured by the Functional Assessment of Cancer Therapy for Lung Cancer (FACT-L) questionnaire","timeFrame":"At visits 2-8, then every 6 weeks until progression, at progression or treatment discontinuation, and every 8 weeks after progression until PFS analysis data cut off."},{"measure":"Time to Worsening in FACT-L Total Score","description":"A worsening is defined as a change from baseline of ≤ -6 (0-136 score range). Measured by the Functional Assessment of Cancer Therapy for Lung Cancer (FACT-L) questionnaire","timeFrame":"At visits 2-8, then every 6 weeks until progression, at progression or treatment discontinuation, and every 8 weeks after progression until PFS analysis data cut off."},{"measure":"Improvement in Lung Cancer Subscale","description":"An improvement is defined as a change from baseline of ≥ +2 (0-28 score range). Measured by the Functional Assessment of Cancer Therapy for Lung Cancer (FACT-L) questionnaire","timeFrame":"At visits 2-8, then every 6 weeks until progression, at progression or treatment discontinuation, and every 8 weeks after progression until PFS analysis data cut off."},{"measure":"Time to Worsening in Lung Cancer Subscale","description":"A worsening is defined as a change from baseline of ≤ -2 (0-28 score range). Measured by the Functional Assessment of Cancer Therapy for Lung Cancer (FACT-L) questionnaire","timeFrame":"At visits 2-8, then every 6 weeks until progression, at progression or treatment discontinuation, and every 8 weeks after progression until PFS analysis data cut off."}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or female patients aged 18 years or older (For Japan only- male or female patients aged 20 years or older)\n* Cytological or histological confirmation of NSCLC other than predominantly squamous cell histology with an activating EGFR TK mutation as determined locally\n* Patients with documented 'acquired resistance' on first line gefitinib\n* Patients suitable to start cisplatin based pemetrexed combination chemotherapy.\n* Provision of informed consent prior to any study specific procedures.\n\nExclusion Criteria:\n\n* Prior chemotherapy or other systemic anti-cancer treatment (excluding gefitinib). Palliative bone radiotherapy must be completed at least 2 weeks before start of study treatment with no persistent radiation toxicity).\n* Past medical history of interstitial lung disease, drug-induced interstitial disease, radiation pneumonitis which required steroid treatment or any evidence of clinically active interstitial lung disease\n* Other co-existing malignancies or malignancies diagnosed within the last 5 years, with the exception of basal cell carcinoma or cervical cancer in situ or completely resected intramucosal gastric cancer\n* Any evidence of severe of uncontrolled systemic disease Treatment with an investigational drug within 4 weeks before randomization","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"130 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Yuri Rukazenkov, MD PhD, GCL Oncology","affiliation":"AstraZeneca Global R&D, Alderley park, Cheshire, SK10 4TG, UK","role":"STUDY_DIRECTOR"},{"name":"Tony Mok, M.D.","affiliation":"Department of Clinical Oncology, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, N.T., Hong KongDepartment of Clinical Oncology, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, N.T., Hong Kong","role":"PRINCIPAL_INVESTIGATOR"},{"name":"Jean-Charles Soria, MD, PHD","affiliation":"Institute Gustave Roussy, France","role":"PRINCIPAL_INVESTIGATOR"},{"name":"Haiyi Jiang, M.D. MSc","affiliation":"Zhangjiang Hi-tech Park, 3F, Room 3102, 199 Liangjing Road, Pudong Shanghai, postal code:201203","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Research Site","city":"Beijing","zip":"100020","country":"China","geoPoint":{"lat":39.9075,"lon":116.39723}},{"facility":"Research Site","city":"Beijing","zip":"100021","country":"China","geoPoint":{"lat":39.9075,"lon":116.39723}},{"facility":"Research Site","city":"Beijing","zip":"100071","country":"China","geoPoint":{"lat":39.9075,"lon":116.39723}},{"facility":"Research Site","city":"Beijing","zip":"100730","country":"China","geoPoint":{"lat":39.9075,"lon":116.39723}},{"facility":"Research Site","city":"Beijing","zip":"100853","country":"China","geoPoint":{"lat":39.9075,"lon":116.39723}},{"facility":"Research Site","city":"Beijing","zip":"101149","country":"China","geoPoint":{"lat":39.9075,"lon":116.39723}},{"facility":"Research Site","city":"Changchun","zip":"130012","country":"China","geoPoint":{"lat":43.88,"lon":125.32278}},{"facility":"Research Site","city":"Changchun","zip":"130021","country":"China","geoPoint":{"lat":43.88,"lon":125.32278}},{"facility":"Research Site","city":"Chengdu","zip":"610041","country":"China","geoPoint":{"lat":30.66667,"lon":104.06667}},{"facility":"Research Site","city":"Chengdu","zip":"610042","country":"China","geoPoint":{"lat":30.66667,"lon":104.06667}},{"facility":"Research Site","city":"Dalian","zip":"116011","country":"China","geoPoint":{"lat":38.91222,"lon":121.60222}},{"facility":"Research Site","city":"Guangzhou","zip":"510000","country":"China","geoPoint":{"lat":23.11667,"lon":113.25}},{"facility":"Research Site","city":"Guangzhou","zip":"510120","country":"China","geoPoint":{"lat":23.11667,"lon":113.25}},{"facility":"Research Site","city":"Hangzhou","zip":"310003","country":"China","geoPoint":{"lat":30.29365,"lon":120.16142}},{"facility":"Research Site","city":"Kunming","zip":"650118","country":"China","geoPoint":{"lat":25.03889,"lon":102.71833}},{"facility":"Research Site","city":"Nanjing","zip":"210002","country":"China","geoPoint":{"lat":32.06167,"lon":118.77778}},{"facility":"Research Site","city":"Shanghai","zip":"200030","country":"China","geoPoint":{"lat":31.22222,"lon":121.45806}},{"facility":"Research Site","city":"Shanghai","zip":"200032","country":"China","geoPoint":{"lat":31.22222,"lon":121.45806}},{"facility":"Research Site","city":"Shenyang","zip":"110001","country":"China","geoPoint":{"lat":41.79222,"lon":123.43278}},{"facility":"Research Site","city":"Shijiazhuang","zip":"050011","country":"China","geoPoint":{"lat":38.04139,"lon":114.47861}},{"facility":"Research Site","city":"Suzhou","zip":"215004","country":"China","geoPoint":{"lat":31.30408,"lon":120.59538}},{"facility":"Research Site","city":"Taiyuan","zip":"030000","country":"China","geoPoint":{"lat":37.86944,"lon":112.56028}},{"facility":"Research Site","city":"Ürümqi","zip":"830000","country":"China","geoPoint":{"lat":43.80096,"lon":87.60046}},{"facility":"Research Site","city":"Wuhan","zip":"430022","country":"China","geoPoint":{"lat":30.58333,"lon":114.26667}},{"facility":"Research Site","city":"Xi'an","zip":"710061","country":"China","geoPoint":{"lat":34.25833,"lon":108.92861}},{"facility":"Research Site","city":"Clermont-Ferrand","zip":"63003","country":"France","geoPoint":{"lat":45.77969,"lon":3.08682}},{"facility":"Research Site","city":"Lille","zip":"59037","country":"France","geoPoint":{"lat":50.63391,"lon":3.05512}},{"facility":"Research Site","city":"Lyon","zip":"69373","country":"France","geoPoint":{"lat":45.74906,"lon":4.84789}},{"facility":"Research Site","city":"Paris","zip":"75020","country":"France","geoPoint":{"lat":48.85341,"lon":2.3488}},{"facility":"Research Site","city":"Villejuif","zip":"94805","country":"France","geoPoint":{"lat":48.7939,"lon":2.35992}},{"facility":"Research Site","city":"Hamburg","zip":"21075","country":"Germany","geoPoint":{"lat":53.55073,"lon":9.99302}},{"facility":"Research Site","city":"Löwenstein","zip":"74245","country":"Germany","geoPoint":{"lat":49.09558,"lon":9.38}},{"facility":"Research Site","city":"Würzburg","zip":"97067","country":"Germany","geoPoint":{"lat":49.79391,"lon":9.95121}},{"facility":"Research Site","city":"Hong Kong","country":"Hong Kong","geoPoint":{"lat":22.27832,"lon":114.17469}},{"facility":"Research Site","city":"Shatin","country":"Hong Kong","geoPoint":{"lat":22.38333,"lon":114.18333}},{"facility":"Research Site","city":"Budapest","zip":"1121","country":"Hungary","geoPoint":{"lat":47.49835,"lon":19.04045}},{"facility":"Research Site","city":"Budapest","zip":"1145","country":"Hungary","geoPoint":{"lat":47.49835,"lon":19.04045}},{"facility":"Research Site","city":"Genova","zip":"16100","country":"Italy","geoPoint":{"lat":45.21604,"lon":11.87211}},{"facility":"Research Site","city":"Parma","zip":"43126","country":"Italy","geoPoint":{"lat":44.79935,"lon":10.32618}},{"facility":"Research Site","city":"Perugia","zip":"06132","country":"Italy","geoPoint":{"lat":43.1122,"lon":12.38878}},{"facility":"Research Site","city":"Pisa","zip":"56124","country":"Italy","geoPoint":{"lat":43.70853,"lon":10.4036}},{"facility":"Research Site","city":"Roma","zip":"00128","country":"Italy","geoPoint":{"lat":44.99364,"lon":11.10642}},{"facility":"Research Site","city":"Roma","zip":"00144","country":"Italy","geoPoint":{"lat":44.99364,"lon":11.10642}},{"facility":"Research Site","city":"Rozzano","zip":"20089","country":"Italy","geoPoint":{"lat":45.38193,"lon":9.1559}},{"facility":"Research Site","city":"Fukuoka","zip":"811-1395","country":"Japan","geoPoint":{"lat":33.6,"lon":130.41667}},{"facility":"Research Site","city":"Kashiwa","zip":"277-8577","country":"Japan","geoPoint":{"lat":35.86224,"lon":139.97732}},{"facility":"Research Site","city":"Sakaishi","zip":"591-8555","country":"Japan","geoPoint":{"lat":33.41239,"lon":132.71218}},{"facility":"Research Site","city":"Sayama","zip":"589-8511","country":"Japan","geoPoint":{"lat":34.51685,"lon":135.56298}},{"facility":"Research Site","city":"Sunto-gun","zip":"411-8777","country":"Japan"},{"facility":"Research Site","city":"Saint Petersburg","zip":"197022","country":"Russia","geoPoint":{"lat":59.93863,"lon":30.31413}},{"facility":"Research Site","city":"Seoul","zip":"05505","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Research Site","city":"Seoul","zip":"135-710","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Research Site","city":"Barcelona","zip":"08003","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"Research Site","city":"Barcelona","zip":"08025","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"Research Site","city":"Madrid","zip":"28041","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"Research Site","city":"Majadahonda","zip":"28222","country":"Spain","geoPoint":{"lat":40.47353,"lon":-3.87182}},{"facility":"Research Site","city":"Málaga","zip":"29010","country":"Spain","geoPoint":{"lat":36.72016,"lon":-4.42034}},{"facility":"Research Site","city":"Seville","zip":"41009","country":"Spain","geoPoint":{"lat":37.38283,"lon":-5.97317}},{"facility":"Research Site","city":"Zaragoza","zip":"50009","country":"Spain","geoPoint":{"lat":41.65606,"lon":-0.87734}},{"facility":"Research Site","city":"Taichung","zip":"40705","country":"Taiwan","geoPoint":{"lat":24.1469,"lon":120.6839}},{"facility":"Research Site","city":"Taipei","zip":"10002","country":"Taiwan","geoPoint":{"lat":25.05306,"lon":121.52639}}]},"referencesModule":{"references":[{"pmid":"26159065","type":"DERIVED","citation":"Soria JC, Wu YL, Nakagawa K, Kim SW, Yang JJ, Ahn MJ, Wang J, Yang JC, Lu Y, Atagi S, Ponce S, Lee DH, Liu Y, Yoh K, Zhou JY, Shi X, Webster A, Jiang H, Mok TS. Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial. Lancet Oncol. 2015 Aug;16(8):990-8. doi: 10.1016/S1470-2045(15)00121-7. Epub 2015 Jul 6."}],"seeAlsoLinks":[{"label":"D791LC00001\\_CSR\\_Synopsis","url":"http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=612&filename=D791LC00001_CSR_Synopsis.pdf"},{"label":"D791LC00001REDACTED\\_PROTOCOL","url":"http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=612&filename=D791LC00001REDACTED_PROTOCOL.pdf"}]}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"265 patients were randomised. Randomised patients had epidermal growth factor receptor (EGFR) mutation-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) and who had progressed on first-line gefitinib treatment","recruitmentDetails":"A total of 265 (100%) patients randomised were from 61 centres in 11 countries: 133 patients to the gefitinib group and132 patients to the placebo group. Patients received maximum of 6 cycles cisplatin plus pemetrexed chemotherapy in addition to the randomised treatment (gefitinib or placebo).","groups":[{"id":"FG000","title":"Gefitinib","description":"Gefitinib 250mg and cisplatin plus pemetrexed combination chemotherapy"},{"id":"FG001","title":"Placebo","description":"Placebo and cisplatin plus pemetrexed combination chemotherapy."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"133"},{"groupId":"FG001","numSubjects":"132"}]},{"type":"Received Treatment","achievements":[{"groupId":"FG000","numSubjects":"132"},{"groupId":"FG001","numSubjects":"132"}]},{"type":"Did Not Receive Treatment","achievements":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","comment":"Patients are ongoing in the study","numSubjects":"70"},{"groupId":"FG001","comment":"Patients are ongoing in the study","numSubjects":"86"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"63"},{"groupId":"FG001","numSubjects":"46"}]}],"dropWithdraws":[{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"50"},{"groupId":"FG001","numSubjects":"37"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}]},{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"12"},{"groupId":"FG001","numSubjects":"7"}]},{"type":"Eligibility criteria not fulfilled","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Gefitinib","description":"Gefitinib 250mg and cisplatin plus pemetrexed combination chemotherapy"},{"id":"BG001","title":"Placebo","description":"Placebo and cisplatin plus pemetrexed combination chemotherapy."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"133"},{"groupId":"BG001","value":"132"},{"groupId":"BG002","value":"265"}]}],"measures":[{"title":"Age, Customized","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"<65 years","categories":[{"measurements":[{"groupId":"BG000","value":"90"},{"groupId":"BG001","value":"98"},{"groupId":"BG002","value":"188"}]}]},{"title":">=65 years","categories":[{"measurements":[{"groupId":"BG000","value":"43"},{"groupId":"BG001","value":"34"},{"groupId":"BG002","value":"77"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"87"},{"groupId":"BG001","value":"84"},{"groupId":"BG002","value":"171"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"46"},{"groupId":"BG001","value":"48"},{"groupId":"BG002","value":"94"}]}]}]},{"title":"Race/Ethnicity, Customized","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"Asian","categories":[{"measurements":[{"groupId":"BG000","value":"104"},{"groupId":"BG001","value":"102"},{"groupId":"BG002","value":"206"}]}]},{"title":"Black or African American","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}]}]},{"title":"White","categories":[{"measurements":[{"groupId":"BG000","value":"29"},{"groupId":"BG001","value":"29"},{"groupId":"BG002","value":"58"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Progression-Free Survival (Site Read, Investigator Assessment)","description":"PFS is the time from randomisation until the date of objective disease progression as defined by Response Evaluation Criteria In Solid Tumours (RECIST version 1.1) or death (by any cause in the absence of progression). Progression is defined using RECIST (v1.1), as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5mm.","populationDescription":"Full analysis set (all treated patients)","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Patients with a progression event","timeFrame":"Radiologic evaluations were carried out every 6 weeks from randomization until documented progression, withdrawal of consent, loss to follow up, death or the primary data cut off (DCO) for the analysis, assessed up to 50 weeks","groups":[{"id":"OG000","title":"Gefitinib","description":"Gefitinib 250mg and cisplatin plus pemetrexed combination chemotherapy"},{"id":"OG001","title":"Placebo","description":"Placebo and cisplatin plus pemetrexed combination chemotherapy."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"133"},{"groupId":"OG001","value":"132"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"98","lowerLimit":"4.5","upperLimit":"5.7"},{"groupId":"OG001","value":"107","lowerLimit":"4.6","upperLimit":"5.5"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.273","statisticalMethod":"Cox Proportional Hazards","paramType":"Hazard Ratio (HR)","paramValue":"0.86","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.65","ciUpperLimit":"1.13"}]},{"type":"PRIMARY","title":"Median Progression-Free Survival (Site Read, Investigator Assessment)","description":"PFS is the time from randomisation until the date of objective disease progression as defined by Response Evaluation Criteria In Solid Tumours (RECIST version 1.1) or death (by any cause in the absence of progression). Progression is defined using RECIST (v1.1), as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5mm.","populationDescription":"Full analysis set (all treated patients)","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"Radiologic evaluations were carried out every 6 weeks from randomization until documented progression, withdrawal of consent, loss to follow up, death or the primary data cut off (DCO) for the analysis, assessed up to 50 weeks","groups":[{"id":"OG000","title":"Gefitinib","description":"Gefitinib 250mg and cisplatin plus pemetrexed combination chemotherapy"},{"id":"OG001","title":"Placebo","description":"Placebo and cisplatin plus pemetrexed combination chemotherapy."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"133"},{"groupId":"OG001","value":"132"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.4","lowerLimit":"4.5","upperLimit":"5.7"},{"groupId":"OG001","value":"5.4","lowerLimit":"4.6","upperLimit":"5.5"}]}]}]},{"type":"SECONDARY","title":"Overall Survival (OS)","description":"OS is the time from the date of randomisation until death due to any cause. Any subject not known to have died at the time of analysis will be censored based on the last recorded date on which the subject was known to be alive.","populationDescription":"Full analysis set","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Number of patients with an OS event","timeFrame":"Following progression survival data was collected every 8 weeks until documentation of death, withdrawal of consent, loss to follow-up or the final data cut-off, whichever occurs first.","groups":[{"id":"OG000","title":"Gefitinib","description":"Gefitinib 250mg and cisplatin plus pemetrexed combination chemotherapy"},{"id":"OG001","title":"Placebo","description":"Placebo and cisplatin plus pemetrexed combination chemotherapy."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"133"},{"groupId":"OG001","value":"132"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50","lowerLimit":"10.4","upperLimit":"19.0"},{"groupId":"OG001","value":"37","lowerLimit":"15.6","upperLimit":"NA"}]}]}]},{"type":"SECONDARY","title":"Median Overall Survival (OS) at Time of PFS Analysis","populationDescription":"Full analysis set","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"Baseline and then every 6 weeks after randomization until objective disease progression. OS is then assessed 8 weekly following PFS progression up to PFS analysis data cut off.","groups":[{"id":"OG000","title":"Gefitinib","description":"Gefitinib 250mg and cisplatin plus pemetrexed combination chemotherapy"},{"id":"OG001","title":"Placebo","description":"Placebo and cisplatin plus pemetrexed combination chemotherapy."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"133"},{"groupId":"OG001","value":"132"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.8","lowerLimit":"10.4","upperLimit":"19.0"},{"groupId":"OG001","value":"17.2","lowerLimit":"15.6","upperLimit":"NA","comment":"NA because value was Not Calculated, due to insufficient number of participants with events"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.029","statisticalMethod":"Cox Proportional Hazards","paramType":"Hazard Ratio (HR)","paramValue":"1.62","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.05","ciUpperLimit":"2.52"}]},{"type":"SECONDARY","title":"Objective Response Rate (ORR) (Site Read Data)","description":"ORR rate is defined as the number (%) of subjects with at least one visit response of Complete Response (CR) or Partial Response (PR) , as defined by Response Evaluation Criteria in Solid Tumours (RECIST v1.1) for target lesions and assessed by CT or MRI. CR, Disappearance of all target lesions; PR, ≥30% decrease in the sum of the longest diameter of target lesions. Data obtained up until progression, or last evaluable assessment in the absence of progression, was included in the assessment of ORR.","populationDescription":"Full analysis set","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of Participants","timeFrame":"Radiologic evaluations were carried out every 6 weeks from randomization until documented progression, withdrawal of consent, loss to follow up, death or the primary data cut off (DCO) for the analysis.","groups":[{"id":"OG000","title":"Gefitinib","description":"Gefitinib 250mg and cisplatin plus pemetrexed combination chemotherapy"},{"id":"OG001","title":"Placebo","description":"Placebo and cisplatin plus pemetrexed combination chemotherapy."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"133"},{"groupId":"OG001","value":"132"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31.6","lowerLimit":"0.55","upperLimit":"1.55"},{"groupId":"OG001","value":"34.1","lowerLimit":"0.55","upperLimit":"1.55"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.760","statisticalMethod":"Regression, Logistic","paramType":"Odds Ratio (OR)","paramValue":"0.92","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.55","ciUpperLimit":"1.55"}]},{"type":"SECONDARY","title":"Disease Control Rate (DCR)","description":"DCR is the percentage of patients who achieve disease control at 6 weeks following randomisation. DCR is defined as a Best Objective Response (BOR) of Complete Response, Partial Response or Stable Disease, as defined by Response Evaluation Criteria in Solid Tumours (RECIST v1.1) for target lesions and assessed by CT or MRI. CR, Disappearance of all target lesions; PR, ≥30% decrease in the sum of the longest diameter of target lesions; SD, neither sufficient shrinkage to qualify for PR not sufficient increase to qualify for Progressive Disease (PD); PD, ≥20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study, and the sum must have shown an absolute increase of ≥5mm","populationDescription":"Full analysis set","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of Participants","timeFrame":"Radiologic evaluations were carried out every 6 weeks from randomization until documented progression, withdrawal of consent, loss to follow up, death or the primary data cut off (DCO) for the analysis.","groups":[{"id":"OG000","title":"Gefitinib","description":"Gefitinib 250mg and cisplatin plus pemetrexed combination chemotherapy"},{"id":"OG001","title":"Placebo","description":"Placebo and cisplatin plus pemetrexed combination chemotherapy."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"133"},{"groupId":"OG001","value":"132"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"84.2","lowerLimit":"0.74","upperLimit":"2.62"},{"groupId":"OG001","value":"78.8","lowerLimit":"0.74","upperLimit":"2.62"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.308","statisticalMethod":"Regression, Logistic","paramType":"Odds Ratio (OR)","paramValue":"1.39","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.74","ciUpperLimit":"2.62"}]},{"type":"SECONDARY","title":"Improvement in Trial Outcome Index","description":"An improvement is defined as a change from baseline of ≥ +6 (0-84 score range). Measured by the Functional Assessment of Cancer Therapy for Lung Cancer (FACT-L) questionnaire.","populationDescription":"Evaluable-for-QoL","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Number of participants improving","timeFrame":"At visits 2-8, then every 6 weeks until progression, at progression or treatment discontinuation, and every 8 weeks after progression until PFS analysis data cut off.","groups":[{"id":"OG000","title":"Gefitinib","description":"Gefitinib 250mg and cisplatin plus pemetrexed combination chemotherapy"},{"id":"OG001","title":"Placebo","description":"Placebo and cisplatin plus pemetrexed combination chemotherapy."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"124"},{"groupId":"OG001","value":"129"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36","lowerLimit":"0.74","upperLimit":"2.62"},{"groupId":"OG001","value":"39","lowerLimit":"0.74","upperLimit":"2.62"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.770","statisticalMethod":"Regression, Logistic","paramType":"Odds Ratio (OR)","paramValue":"0.92","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.53","ciUpperLimit":"1.59"}]},{"type":"SECONDARY","title":"Time to Worsening in Trial Outcome Index","description":"A worsening is defined as a change from baseline of ≤ -6 (0-84 score range). Measured by the Functional Assessment of Cancer Therapy for Lung Cancer (FACT-L) questionnaire","populationDescription":"Evaluable-for-QoL","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Weeks","timeFrame":"At visits 2-8, then every 6 weeks until progression, at progression or treatment discontinuation, and every 8 weeks after progression until PFS analysis data cut off.","groups":[{"id":"OG000","title":"Gefitinib","description":"Gefitinib 250mg and cisplatin plus pemetrexed combination chemotherapy"},{"id":"OG001","title":"Placebo","description":"Placebo and cisplatin plus pemetrexed combination chemotherapy."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"124"},{"groupId":"OG001","value":"129"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.1","lowerLimit":"8.7","upperLimit":"18.1"},{"groupId":"OG001","value":"9.4","lowerLimit":"7.7","upperLimit":"13.4"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.507","statisticalMethod":"Cox Proportional Hazards","paramType":"Hazard Ratio (HR)","paramValue":"0.91","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.68","ciUpperLimit":"1.21"}]},{"type":"SECONDARY","title":"Improvement in FACT-L Total Score","description":"An improvement is defined as a change from baseline of ≥ +6 (0-136 score range). Measured by the Functional Assessment of Cancer Therapy for Lung Cancer (FACT-L) questionnaire","populationDescription":"Evaluable-for-QoL","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Number of patients improving","timeFrame":"At visits 2-8, then every 6 weeks until progression, at progression or treatment discontinuation, and every 8 weeks after progression until PFS analysis data cut off.","groups":[{"id":"OG000","title":"Gefitinib","description":"Gefitinib 250mg and cisplatin plus pemetrexed combination chemotherapy"},{"id":"OG001","title":"Placebo","description":"Placebo and cisplatin plus pemetrexed combination chemotherapy."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"124"},{"groupId":"OG001","value":"129"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"44","lowerLimit":"0.74","upperLimit":"2.62"},{"groupId":"OG001","value":"49","lowerLimit":"0.74","upperLimit":"2.62"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.725","statisticalMethod":"Regression, Logistic","paramType":"Odds Ratio (OR)","paramValue":"0.91","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.54","ciUpperLimit":"1.53"}]},{"type":"SECONDARY","title":"Time to Worsening in FACT-L Total Score","description":"A worsening is defined as a change from baseline of ≤ -6 (0-136 score range). Measured by the Functional Assessment of Cancer Therapy for Lung Cancer (FACT-L) questionnaire","populationDescription":"Evaluable-for-QoL","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Weeks","timeFrame":"At visits 2-8, then every 6 weeks until progression, at progression or treatment discontinuation, and every 8 weeks after progression until PFS analysis data cut off.","groups":[{"id":"OG000","title":"Gefitinib","description":"Gefitinib 250mg and cisplatin plus pemetrexed combination chemotherapy"},{"id":"OG001","title":"Placebo","description":"Placebo and cisplatin plus pemetrexed combination chemotherapy."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"124"},{"groupId":"OG001","value":"129"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.0","lowerLimit":"6.0","upperLimit":"15.0"},{"groupId":"OG001","value":"8.9","lowerLimit":"6.0","upperLimit":"9.9"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.575","statisticalMethod":"Cox Proportional Hazards","paramType":"Hazard Ratio (HR)","paramValue":"0.92","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.69","ciUpperLimit":"1.23"}]},{"type":"SECONDARY","title":"Improvement in Lung Cancer Subscale","description":"An improvement is defined as a change from baseline of ≥ +2 (0-28 score range). Measured by the Functional Assessment of Cancer Therapy for Lung Cancer (FACT-L) questionnaire","populationDescription":"Evaluable-for-QoL","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Number of participants improving","timeFrame":"At visits 2-8, then every 6 weeks until progression, at progression or treatment discontinuation, and every 8 weeks after progression until PFS analysis data cut off.","groups":[{"id":"OG000","title":"Gefitinib","description":"Gefitinib 250mg and cisplatin plus pemetrexed combination chemotherapy"},{"id":"OG001","title":"Placebo","description":"Placebo and cisplatin plus pemetrexed combination chemotherapy."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"124"},{"groupId":"OG001","value":"129"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"54"},{"groupId":"OG001","value":"55"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.959","statisticalMethod":"Regression, Logistic","paramType":"Odds Ratio (OR)","paramValue":"1.01","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.61","ciUpperLimit":"1.68"}]},{"type":"SECONDARY","title":"Time to Worsening in Lung Cancer Subscale","description":"A worsening is defined as a change from baseline of ≤ -2 (0-28 score range). Measured by the Functional Assessment of Cancer Therapy for Lung Cancer (FACT-L) questionnaire","populationDescription":"Evaluable-for-QoL","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Weeks","timeFrame":"At visits 2-8, then every 6 weeks until progression, at progression or treatment discontinuation, and every 8 weeks after progression until PFS analysis data cut off.","groups":[{"id":"OG000","title":"Gefitinib","description":"Gefitinib 250mg and cisplatin plus pemetrexed combination chemotherapy"},{"id":"OG001","title":"Placebo","description":"Placebo and cisplatin plus pemetrexed combination chemotherapy."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"124"},{"groupId":"OG001","value":"129"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.6","lowerLimit":"9.1","upperLimit":"24.3"},{"groupId":"OG001","value":"9.1","lowerLimit":"6.1","upperLimit":"23.9"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.437","statisticalMethod":"Cox Proportional Hazards","paramType":"Hazard Ratio (HR)","paramValue":"0.89","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.66","ciUpperLimit":"1.20"}]}]},"adverseEventsModule":{"frequencyThreshold":"0","timeFrame":"AEs were collected from signature of informed consent, throughout the treatment period until 30 days after discontinuation of the investigational product","eventGroups":[{"id":"EG000","title":"Gefitinib 250 mg","seriousNumAffected":38,"seriousNumAtRisk":132,"otherNumAffected":125,"otherNumAtRisk":132},{"id":"EG001","title":"Placebo","seriousNumAffected":28,"seriousNumAtRisk":132,"otherNumAffected":129,"otherNumAtRisk":132}],"seriousEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Bone marrow failure","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Febrile bone marrow aplasia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Cardiac failure","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Pericardial effusion","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Wolff-Parkinson-White syndrome","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Inappropriate antidiuretic hormone secretion","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Abdominal discomfort","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Dysphagia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Enteritis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Gastric perforation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Gastrointestinal disorder","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":132}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Multi-organ failure","organSystem":"General disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Anaphylactic shock","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Anal abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Bronchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Cellulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Lung infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Paronychia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":4,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Craniocerebral injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Fall","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Thermal burn","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":132},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":132}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Joint swelling","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Muscular weakness","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Musculoskeletal pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Osteonecrosis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Aphasia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Cerebral infarction","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Cerebral ischaemia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Cerebrovascular accident","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Cognitive disorder","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Epilepsy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Haemorrhage intracranial","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Loss of consciousness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Seizure","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Transient ischaemic attack","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Delirium","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Acute kidney injury","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Nephrolithiasis","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Renal failure","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Asthma","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Haemothorax","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Pleural effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Circulatory collapse","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Embolism","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Orthostatic hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Peripheral artery stenosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Vena cava thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Venous thrombosis limb","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]}],"otherEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":56,"numAffected":40,"numAtRisk":132},{"groupId":"EG001","numEvents":40,"numAffected":32,"numAtRisk":132}]},{"term":"Bone marrow failure","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":4,"numAtRisk":132},{"groupId":"EG001","numEvents":21,"numAffected":8,"numAtRisk":132}]},{"term":"Erythropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":9,"numAffected":3,"numAtRisk":132}]},{"term":"Febrile neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Granulocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":132},{"groupId":"EG001","numEvents":4,"numAffected":3,"numAtRisk":132}]},{"term":"Hypercoagulation","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Leukocytosis","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Leukopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":61,"numAffected":27,"numAtRisk":132},{"groupId":"EG001","numEvents":53,"numAffected":22,"numAtRisk":132}]},{"term":"Lymphadenitis","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Lymphopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":59,"numAffected":29,"numAtRisk":132},{"groupId":"EG001","numEvents":69,"numAffected":28,"numAtRisk":132}]},{"term":"Pancytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":7,"numAtRisk":132},{"groupId":"EG001","numEvents":11,"numAffected":9,"numAtRisk":132}]},{"term":"Angina pectoris","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Arrhythmia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Cardiac failure","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Myocardial ischaemia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Nodal arrhythmia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Palpitations","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":132}]},{"term":"Sinus tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":132},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":132}]},{"term":"Tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Ventricular extrasystoles","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Wolff-Parkinson-White syndrome","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Ichthyosis","organSystem":"Congenital, familial and genetic disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Deafness","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Hearing impaired","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Hypoacusis","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Ototoxicity","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Tinnitus","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":6,"numAtRisk":132},{"groupId":"EG001","numEvents":6,"numAffected":4,"numAtRisk":132}]},{"term":"Vertigo","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":132}]},{"term":"Vertigo positional","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Blepharitis","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Cataract","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Diplopia","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Dry eye","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Eczema eyelids","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Eye discharge","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Eye pain","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Eyelid oedema","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Keratitis","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Lacrimation increased","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Punctate keratitis","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Trichiasis","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Visual impairment","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Xerophthalmia","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":132},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":132}]},{"term":"Abdominal distension","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":132},{"groupId":"EG001","numEvents":4,"numAffected":3,"numAtRisk":132}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":7,"numAtRisk":132},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":132}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":16,"numAffected":12,"numAtRisk":132},{"groupId":"EG001","numEvents":16,"numAffected":13,"numAtRisk":132}]},{"term":"Cheilitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":58,"numAffected":34,"numAtRisk":132},{"groupId":"EG001","numEvents":56,"numAffected":35,"numAtRisk":132}]},{"term":"Dental caries","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":71,"numAffected":43,"numAtRisk":132},{"groupId":"EG001","numEvents":22,"numAffected":19,"numAtRisk":132}]},{"term":"Duodenal ulcer","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Dyspepsia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":132},{"groupId":"EG001","numEvents":6,"numAffected":5,"numAtRisk":132}]},{"term":"Dysphagia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Enteritis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Enterocolitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Epigastric discomfort","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Flatulence","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Gastric dilatation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Gastritis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":132},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":132}]},{"term":"Gastrointestinal disorder","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":5,"numAtRisk":132},{"groupId":"EG001","numEvents":10,"numAffected":5,"numAtRisk":132}]},{"term":"Gastrointestinal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Gastrooesophageal reflux disease","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":132}]},{"term":"Gingival bleeding","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Gingival pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Gingival swelling","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Haematemesis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Haemorrhoidal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Haemorrhoids","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Impaired gastric emptying","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":4,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Mouth ulceration","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":180,"numAffected":84,"numAtRisk":132},{"groupId":"EG001","numEvents":160,"numAffected":80,"numAtRisk":132}]},{"term":"Oesophagitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Oral disorder","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Periodontal disease","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Stomatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":15,"numAffected":14,"numAtRisk":132},{"groupId":"EG001","numEvents":8,"numAffected":5,"numAtRisk":132}]},{"term":"Upper gastrointestinal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":96,"numAffected":54,"numAtRisk":132},{"groupId":"EG001","numEvents":75,"numAffected":43,"numAtRisk":132}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":27,"numAffected":15,"numAtRisk":132},{"groupId":"EG001","numEvents":43,"numAffected":30,"numAtRisk":132}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Chills","organSystem":"General disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Face oedema","organSystem":"General disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":37,"numAffected":28,"numAtRisk":132},{"groupId":"EG001","numEvents":31,"numAffected":23,"numAtRisk":132}]},{"term":"General physical health deterioration","organSystem":"General disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Generalised oedema","organSystem":"General disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Influenza like illness","organSystem":"General disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":132},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":132}]},{"term":"Local swelling","organSystem":"General disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Malaise","organSystem":"General disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":10,"numAtRisk":132},{"groupId":"EG001","numEvents":15,"numAffected":9,"numAtRisk":132}]},{"term":"Mucosal inflammation","organSystem":"General disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":6,"numAtRisk":132},{"groupId":"EG001","numEvents":4,"numAffected":3,"numAtRisk":132}]},{"term":"Nodule","organSystem":"General disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Non-cardiac chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Oedema","organSystem":"General disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Oedema peripheral","organSystem":"General disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":5,"numAtRisk":132},{"groupId":"EG001","numEvents":5,"numAffected":4,"numAtRisk":132}]},{"term":"Pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Performance status decreased","organSystem":"General disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":24,"numAffected":21,"numAtRisk":132},{"groupId":"EG001","numEvents":15,"numAffected":14,"numAtRisk":132}]},{"term":"Sensation of foreign body","organSystem":"General disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Sense of oppression","organSystem":"General disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Hepatic function abnormal","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":132},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":132}]},{"term":"Hyperbilirubinaemia","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Liver injury","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Anaphylactic shock","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Contrast media allergy","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Bronchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Candida infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":132}]},{"term":"Clostridium difficile colitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Conjunctivitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":8,"numAffected":8,"numAtRisk":132}]},{"term":"Cystitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Folliculitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Gastroenteritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Herpes simplex","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Influenza","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":132},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":132}]},{"term":"Localised infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Lung infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":132},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":132}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":5,"numAtRisk":132},{"groupId":"EG001","numEvents":9,"numAffected":8,"numAtRisk":132}]},{"term":"Oral herpes","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Paronychia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Parotitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Pharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":132},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":132}]},{"term":"Pulmonary tuberculosis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Pyelonephritis acute","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Sinusitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Skin infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Staphylococcal sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Tonsillitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":132},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":132}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":6,"numAtRisk":132},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":132}]},{"term":"Vaginal infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Viral rhinitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Contusion","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Hand fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Procedural pain","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Radius fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Rib fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Thermal burn","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Traumatic haematoma","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Alanine aminotransferase decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":132},{"groupId":"EG001","numEvents":17,"numAffected":11,"numAtRisk":132}]},{"term":"Albumin globulin ratio abnormal","organSystem":"Investigations","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Aspartate aminotransferase decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Aspartate aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":8,"numAtRisk":132},{"groupId":"EG001","numEvents":16,"numAffected":10,"numAtRisk":132}]},{"term":"Blood albumin decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Blood alkaline phosphatase decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Blood alkaline phosphatase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Blood bilirubin decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Blood bilirubin increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":132},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":132}]},{"term":"Blood cholesterol increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":132},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":132}]},{"term":"Blood creatinine increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":14,"numAffected":12,"numAtRisk":132},{"groupId":"EG001","numEvents":17,"numAffected":12,"numAtRisk":132}]},{"term":"Blood potassium decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Blood pressure increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Blood sodium decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Blood urea increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":132},{"groupId":"EG001","numEvents":10,"numAffected":4,"numAtRisk":132}]},{"term":"Blood uric acid increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Breath sounds abnormal","organSystem":"Investigations","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"C-reactive protein increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Computerised tomogram thorax abnormal","organSystem":"Investigations","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Gamma-glutamyltransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":132},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":132}]},{"term":"Haemoglobin decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":8,"numAtRisk":132},{"groupId":"EG001","numEvents":5,"numAffected":4,"numAtRisk":132}]},{"term":"Lymphocyte count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Neutrophil count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":31,"numAffected":16,"numAtRisk":132},{"groupId":"EG001","numEvents":47,"numAffected":22,"numAtRisk":132}]},{"term":"Occult blood","organSystem":"Investigations","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Occult blood positive","organSystem":"Investigations","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Palpatory finding abnormal","organSystem":"Investigations","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Platelet count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":15,"numAffected":9,"numAtRisk":132},{"groupId":"EG001","numEvents":6,"numAffected":3,"numAtRisk":132}]},{"term":"Protein total decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Protein urine","organSystem":"Investigations","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Protein urine present","organSystem":"Investigations","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Total bile acids increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Transaminases increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Weight decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":132},{"groupId":"EG001","numEvents":8,"numAffected":5,"numAtRisk":132}]},{"term":"Weight increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":3,"numAtRisk":132},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":132}]},{"term":"White blood cell count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":38,"numAffected":17,"numAtRisk":132},{"groupId":"EG001","numEvents":24,"numAffected":13,"numAtRisk":132}]},{"term":"White blood cells urine positive","organSystem":"Investigations","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":92,"numAffected":64,"numAtRisk":132},{"groupId":"EG001","numEvents":74,"numAffected":45,"numAtRisk":132}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":132},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":132}]},{"term":"Electrolyte imbalance","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Haemochromatosis","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Hypercalcaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":132},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":132}]},{"term":"Hyperglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":4,"numAtRisk":132},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":132}]},{"term":"Hyperkalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":5,"numAffected":1,"numAtRisk":132}]},{"term":"Hyperuricaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Hypoalbuminaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Hypocalcaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":8,"numAtRisk":132},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":132}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":21,"numAffected":13,"numAtRisk":132},{"groupId":"EG001","numEvents":9,"numAffected":5,"numAtRisk":132}]},{"term":"Hypomagnesaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":6,"numAtRisk":132},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":132}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":17,"numAffected":11,"numAtRisk":132},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":132}]},{"term":"Hypophosphataemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Hypoproteinaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":6,"numAtRisk":132},{"groupId":"EG001","numEvents":4,"numAffected":3,"numAtRisk":132}]},{"term":"Metabolic acidosis","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Polydipsia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":8,"numAtRisk":132},{"groupId":"EG001","numEvents":9,"numAffected":7,"numAtRisk":132}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":11,"numAtRisk":132},{"groupId":"EG001","numEvents":15,"numAffected":14,"numAtRisk":132}]},{"term":"Bone pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":132},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":132}]},{"term":"Coccydynia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Flank pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":132},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":132}]},{"term":"Groin pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Intervertebral disc protrusion","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Muscle spasms","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Muscular weakness","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":132},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":132}]},{"term":"Musculoskeletal chest pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":8,"numAtRisk":132},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":132}]},{"term":"Musculoskeletal discomfort","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Musculoskeletal pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":132},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":132}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":15,"numAffected":9,"numAtRisk":132}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":132},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":132}]},{"term":"Periarthritis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Spinal osteoarthritis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Spinal pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Temporomandibular joint syndrome","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Cancer pain","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Tumour pain","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":132},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":132}]},{"term":"Aphasia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Aphonia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Brain injury","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Cerebral ischaemia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Clonic convulsion","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":9,"numAtRisk":132},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":132}]},{"term":"Dysaesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Dysarthria","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Dysgeusia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":132},{"groupId":"EG001","numEvents":10,"numAffected":7,"numAtRisk":132}]},{"term":"Facial nerve disorder","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":14,"numAffected":11,"numAtRisk":132},{"groupId":"EG001","numEvents":24,"numAffected":18,"numAtRisk":132}]},{"term":"Hypoaesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":5,"numAtRisk":132},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":132}]},{"term":"Lethargy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Loss of consciousness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Mental retardation","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":2,"numAtRisk":132},{"groupId":"EG001","numEvents":8,"numAffected":3,"numAtRisk":132}]},{"term":"Migraine","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Monoplegia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Muscle contractions involuntary","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Neuropathy peripheral","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":132},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":132}]},{"term":"Neurotoxicity","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Paraesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":5,"numAtRisk":132},{"groupId":"EG001","numEvents":8,"numAffected":7,"numAtRisk":132}]},{"term":"Peripheral sensory neuropathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":9,"numAtRisk":132},{"groupId":"EG001","numEvents":12,"numAffected":10,"numAtRisk":132}]},{"term":"Petit mal epilepsy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Polyneuropathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Poor quality sleep","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":132}]},{"term":"Presyncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Seizure","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":132},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":132}]},{"term":"Somnolence","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Tremor","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":132}]},{"term":"Vocal cord paralysis","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Agitation","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Anxiety","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":132},{"groupId":"EG001","numEvents":4,"numAffected":3,"numAtRisk":132}]},{"term":"Confusional state","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Delirium","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Depression","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":10,"numAtRisk":132},{"groupId":"EG001","numEvents":7,"numAffected":7,"numAtRisk":132}]},{"term":"Nervousness","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Sleep disorder","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Acute kidney injury","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Chronic kidney disease","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Dysuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Haematuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Nocturia","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Proteinuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Renal disorder","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Renal failure","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Renal impairment","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Renal injury","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Urethral pain","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Urinary incontinence","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Urinary retention","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":132}]},{"term":"Breast mass","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Cystocele","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Dysmenorrhoea","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Genital paraesthesia","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Metrorrhagia","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Oedema genital","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Pelvic pain","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Prostatitis","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Uterine prolapse","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Asthma","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Bronchiectasis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Choking sensation","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":132}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":23,"numAffected":20,"numAtRisk":132},{"groupId":"EG001","numEvents":18,"numAffected":15,"numAtRisk":132}]},{"term":"Dysphonia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":13,"numAffected":12,"numAtRisk":132},{"groupId":"EG001","numEvents":10,"numAffected":9,"numAtRisk":132}]},{"term":"Epistaxis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":132},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":132}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Hiccups","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":7,"numAtRisk":132},{"groupId":"EG001","numEvents":10,"numAffected":7,"numAtRisk":132}]},{"term":"Hypoxia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Laryngeal pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Lung consolidation","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Oropharyngeal pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":132},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":132}]},{"term":"Pleural effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Pleuritic pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Productive cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":10,"numAtRisk":132},{"groupId":"EG001","numEvents":11,"numAffected":10,"numAtRisk":132}]},{"term":"Pulmonary embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Rhinorrhoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":132},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":132}]},{"term":"Sputum discoloured","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Sputum increased","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Upper respiratory tract inflammation","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Acne","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Alopecia","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":9,"numAtRisk":132},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":132}]},{"term":"Dermatitis acneiform","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":8,"numAtRisk":132},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":132}]},{"term":"Dermatitis exfoliative","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Dry skin","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":12,"numAtRisk":132},{"groupId":"EG001","numEvents":8,"numAffected":8,"numAtRisk":132}]},{"term":"Eczema","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":132},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":132}]},{"term":"Erythema","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":132}]},{"term":"Hyperhidrosis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Nail disorder","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Night sweats","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Palmar-plantar erythrodysaesthesia syndrome","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Pigmentation disorder","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":132}]},{"term":"Pruritus","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":8,"numAtRisk":132},{"groupId":"EG001","numEvents":8,"numAffected":7,"numAtRisk":132}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":20,"numAffected":15,"numAtRisk":132},{"groupId":"EG001","numEvents":12,"numAffected":11,"numAtRisk":132}]},{"term":"Rash maculo-papular","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Skin exfoliation","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":132},{"groupId":"EG001","numEvents":3,"numAffected":1,"numAtRisk":132}]},{"term":"Skin fissures","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Skin hyperpigmentation","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":132},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":132}]},{"term":"Skin mass","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Skin toxicity","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Skin ulcer","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Swelling face","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Trichorrhexis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Urticaria","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Deep vein thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":132},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":132}]},{"term":"Embolism","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Erythromelalgia","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Flushing","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":132},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":132}]},{"term":"Hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Peripheral artery thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]},{"term":"Thrombophlebitis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":132}]},{"term":"Thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":132}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"LTE60","restrictiveAgreement":true},"pointOfContact":{"title":"Haiyi Jiang/Asia Medical Director","organization":"AstraZeneca","email":"haiyi.jiang@astrazeneca.com","phone":"+86 21 60302408"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17"},"conditionBrowseModule":{"meshes":[{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"}],"ancestors":[{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D008175","term":"Lung Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000077156","term":"Gefitinib"},{"id":"D000068437","term":"Pemetrexed"},{"id":"D002945","term":"Cisplatin"}],"ancestors":[{"id":"D011799","term":"Quinazolines"},{"id":"D006574","term":"Heterocyclic Compounds, 2-Ring"},{"id":"D000072471","term":"Heterocyclic Compounds, Fused-Ring"},{"id":"D006571","term":"Heterocyclic Compounds"},{"id":"D006147","term":"Guanine"},{"id":"D007042","term":"Hypoxanthines"},{"id":"D011688","term":"Purinones"},{"id":"D011687","term":"Purines"},{"id":"D005971","term":"Glutamates"},{"id":"D024342","term":"Amino Acids, Acidic"},{"id":"D000596","term":"Amino Acids"},{"id":"D000602","term":"Amino Acids, Peptides, and Proteins"},{"id":"D000600","term":"Amino Acids, Dicarboxylic"},{"id":"D017606","term":"Chlorine Compounds"},{"id":"D007287","term":"Inorganic Chemicals"},{"id":"D017672","term":"Nitrogen Compounds"},{"id":"D017671","term":"Platinum Compounds"}]}},"hasResults":true}